<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7254006\results\search\drug\results.xml">
  <result pre="Article Discovery of the FDA-approved drugs bexarotene, cetilistat, diiodohydroxyquinoline, and" exact="abiraterone" post="as potential COVID-19 treatments with a robust two-tier screening"/>
  <result pre="library consisting 1528 FDA-approved drugs. Cetilistat (anti-pancreatic lipase), diiodohydroxyquinoline (anti-parasitic)," exact="abiraterone" post="acetate (synthetic androstane steroid), and bexarotene (antineoplastic retinoid) exhibited"/>
  <result pre="(anti-pancreatic lipase), diiodohydroxyquinoline (anti-parasitic), abiraterone acetate (synthetic androstane steroid), and" exact="bexarotene" post="(antineoplastic retinoid) exhibited potent in vitro anti-SARS-CoV-2 activity (EC50"/>
  <result pre="retinoid) exhibited potent in vitro anti-SARS-CoV-2 activity (EC50 1.13â€&quot;2.01 Î¼M)." exact="Bexarotene" post="demonstrated the highest Cmax:EC50 ratio (1.69) which was higher"/>
  <result pre="compounds studied in this article Abiraterone acetate (PubChem CID: 9821849)" exact="Bexarotene" post="(PubChem CID: 82146) Cetilistat (PubChem CID: 9952916) Diiodohydroxyquinoline (PubChem"/>
  <result pre="Keywords Antiviral Coronavirus COVID-19 Library SARS-CoV-2 Treatment Cetilistat Diiodohydroxyquinoline Abiraterone" exact="Bexarotene" post="1 Introduction Coronaviruses are positive sense, single stranded, enveloped"/>
  <result pre="nucleotide analogue with broad-spectrum antiviral activities including against SARS-CoV-2 [12]." exact="Chloroquine" post="and hydroxychloroquine are mildly immunosuppressive drugs used in the"/>
  <result pre="with broad-spectrum antiviral activities including against SARS-CoV-2 [12]. Chloroquine and" exact="hydroxychloroquine" post="are mildly immunosuppressive drugs used in the treatment of"/>
  <result pre="human [12,16]. A recent non-randomized small-scale clinical study showed that" exact="hydroxychloroquine" post="with or without azithromycin significantly reduced the viral load"/>
  <result pre="non-randomized small-scale clinical study showed that hydroxychloroquine with or without" exact="azithromycin" post="significantly reduced the viral load and duration of virus"/>
  <result pre="and duration of virus shedding in 20 COVID-19 patients [13]." exact="Nafamostat" post="and camostat are a serine protease inhibitor used in"/>
  <result pre="of virus shedding in 20 COVID-19 patients [13]. Nafamostat and" exact="camostat" post="are a serine protease inhibitor used in the treatment"/>
  <result pre="identified a number of drug compounds with anti-SARS-CoV-2 activity, including" exact="bexarotene" post="which has broad-spectrum anti-coronaviral activity and a higher Cmax"/>
  <result pre="bovine serum (FBS, Gibco), 50 U/mL penicillin, and 50 Î¼g/ml" exact="streptomycin" post="as previously described [17]. All experiments involving live SARS-CoV-2"/>
  <result pre="the agarose plugs, the monolayers were stained with 0.7 %" exact="crystal violet" post="(BDH, Merck) and the plaques counted. The percentage of"/>
  <result pre="(-1 to 0 hpi) or post-infection (0 to +1 hpi)." exact="Dimethyl sulfoxide" post="(0.5 %) was included as a negative control. Other"/>
  <result pre="generates a luminescent signal directly proportional to the amount of" exact="adenosine" post="triphosphate (ATP) present and is proportional to the number"/>
  <result pre="at 72 hpi (Table 1 ). Notably, hydroxychloroquine, nafamostat, and" exact="ivermectin" post="which were previously shown to exhibit anti-SARS-CoV-2 activity were"/>
  <result pre="Synthetic androstane steroid Prostate cancer Asenapine (hydrochloride) Atypical antipsychotic Schizophrenia" exact="Azacytidine" post="Nucleoside analogue Myelodysplastic syndrome and acute myeloid leukemia Bexarotene"/>
  <result pre="Schizophrenia Azacytidine Nucleoside analogue Myelodysplastic syndrome and acute myeloid leukemia" exact="Bexarotene" post="Retinoid (retinoid X receptor activator) Cutaneous T cell lymphoma"/>
  <result pre="Hypertension and congestive heart failure Cetilistat Pancreatic lipase inhibitor Obesity" exact="Chloroquine" post="(diphosphate) 4-Aminoquinoline Malaria and amoebic liver abscess Ciclesonide Glucocorticoid"/>
  <result pre="inhibitor Obesity Chloroquine (diphosphate) 4-Aminoquinoline Malaria and amoebic liver abscess" exact="Ciclesonide" post="Glucocorticoid Asthma and allergic rhinitis Diethylstilbestrol Nonsteroidal estrogen Prostate"/>
  <result pre="and amoebic liver abscess Ciclesonide Glucocorticoid Asthma and allergic rhinitis" exact="Diethylstilbestrol" post="Nonsteroidal estrogen Prostate cancer Diiodohydroxyquinoline Quinoline derivative Amoebiasis Fluoxetine"/>
  <result pre="liver abscess Ciclesonide Glucocorticoid Asthma and allergic rhinitis Diethylstilbestrol Nonsteroidal" exact="estrogen" post="Prostate cancer Diiodohydroxyquinoline Quinoline derivative Amoebiasis Fluoxetine (hydrochloride) Selective"/>
  <result pre="Quinoline derivative Amoebiasis Fluoxetine (hydrochloride) Selective serotonin reuptake inhibitor Depression" exact="Micafungin" post="(sodium) Echinocandin Fungal infection Permethrin Insecticide Scabies and lice"/>
  <result pre="Selective serotonin reuptake inhibitor Depression Micafungin (sodium) Echinocandin Fungal infection" exact="Permethrin" post="Insecticide Scabies and lice Pimavanserin Atypical antipsychotic Parkinsonâ€™s disease"/>
  <result pre="Insecticide Scabies and lice Pimavanserin Atypical antipsychotic Parkinsonâ€™s disease psychosis" exact="Raloxifene" post="(hydrochloride) Selective estrogen receptor modulator Osteoporosis Sofalcone Synthetic sophoradin"/>
  <result pre="lice Pimavanserin Atypical antipsychotic Parkinsonâ€™s disease psychosis Raloxifene (hydrochloride) Selective" exact="estrogen" post="receptor modulator Osteoporosis Sofalcone Synthetic sophoradin analogue Gastrointestinal tract"/>
  <result pre="modulator Osteoporosis Sofalcone Synthetic sophoradin analogue Gastrointestinal tract mucosal protection" exact="Tamoxifen" post="(Citrate) Selective estrogen receptor modulator Breast cancer, infertility, and"/>
  <result pre="Synthetic sophoradin analogue Gastrointestinal tract mucosal protection Tamoxifen (Citrate) Selective" exact="estrogen" post="receptor modulator Breast cancer, infertility, and gynecomastia Tilorone (dihydrochloride)"/>
  <result pre="their dose-dependent anti-SARS-CoV-2 effects. Four drug compounds, namely, cetilistat, diiodohydroxyquinoline," exact="abiraterone" post="acetate, and bexarotene were identified as the most potent"/>
  <result pre="effects. Four drug compounds, namely, cetilistat, diiodohydroxyquinoline, abiraterone acetate, and" exact="bexarotene" post="were identified as the most potent anti-SARS-CoV-2 drug compounds"/>
  <result pre="hpi, the 50 % cytotoxic concentrations (CC50) of cetilistat, diiodohydroxyquinoline," exact="abiraterone" post="acetate, and bexarotene were &amp;gt;100 Î¼M, &amp;gt;100 Î¼M, 92.35"/>
  <result pre="% cytotoxic concentrations (CC50) of cetilistat, diiodohydroxyquinoline, abiraterone acetate, and" exact="bexarotene" post="were &amp;gt;100 Î¼M, &amp;gt;100 Î¼M, 92.35 Î¼M, and 38.21"/>
  <result pre="plaque reduction assay are shown: (A) cetilistat, (B) diiodohydroxyquinoline, (C)" exact="abiraterone" post="acetate, and (D) bexarotene. Table 2 Antiviral activity and"/>
  <result pre="&amp;gt;100.00 4.50 1.38 &amp;gt;72.46 Abiraterone (acetate) 92.35 8.40 1.94 47.60" exact="Bexarotene" post="38.21 9.40 2.01 19.01 Abbreviations: CC50, 50 % cytotoxic"/>
  <result pre="CPE development in VeroE6 cells at 72 hpi, while diiodohydroxyquinoline," exact="abiraterone" post="acetate, and bexarotene achieved up to âˆ¼70 % CPE"/>
  <result pre="VeroE6 cells at 72 hpi, while diiodohydroxyquinoline, abiraterone acetate, and" exact="bexarotene" post="achieved up to âˆ¼70 % CPE inhibition (Fig. 5C)."/>
  <result pre="inhibition (Fig. 5C). Overall, these results demonstrated that cetilistat, diiodohydroxyquinoline," exact="abiraterone" post="acetate, and bexarotene inhibited the viral load, viral antigen"/>
  <result pre="Overall, these results demonstrated that cetilistat, diiodohydroxyquinoline, abiraterone acetate, and" exact="bexarotene" post="inhibited the viral load, viral antigen expression, and infectious"/>
  <result pre="(MOI = 0.100) VeroE6 cells after treatment with cetilistat, diiodohydroxyquinoline," exact="abiraterone" post="acetate, or bexarotene (10Î¼M each) and incubated at 37"/>
  <result pre="VeroE6 cells after treatment with cetilistat, diiodohydroxyquinoline, abiraterone acetate, or" exact="bexarotene" post="(10Î¼M each) and incubated at 37 Â°C with 5%"/>
  <result pre="Â± standard deviations. 3.4 Modes of action of cetilistat, diiodohydroxyquinoline," exact="abiraterone" post="acetate, and bexarotene against SARS-CoV-2 To investigate which steps"/>
  <result pre="3.4 Modes of action of cetilistat, diiodohydroxyquinoline, abiraterone acetate, and" exact="bexarotene" post="against SARS-CoV-2 To investigate which steps of the SARS-CoV-2"/>
  <result pre="carried out (Fig. 6 A). Addition of cetilistat, diiodohydroxyquinoline, or" exact="abiraterone" post="acetate at 0 hpi and 3 hpi, but not"/>
  <result pre="events of the SARS-CoV-2 replication cycle (Fig. 6B). In contrast," exact="bexarotene" post="was only effective when co-infected with cells, suggesting that"/>
  <result pre="enabled virus internalization (Fig. 6C). As shown in Fig. 6D," exact="bexarotene" post="did not block virus-host receptor binding, but significantly reduced"/>
  <result pre="reduced viral load during virus internationalization. These results suggested that" exact="bexarotene" post="interfered with SARS-CoV-2 internalization without blocking its binding to"/>
  <result pre="without blocking its binding to the host cell surface. Interestingly," exact="bexarotene" post="also demonstrated antiviral activity against the highly virulent MERS-CoV"/>
  <result pre="DMSO as control. (C) Virus entry assay with or without" exact="bexarotene" post="addition. Viral attachment was performed at 4â&quot;ƒ and then"/>
  <result pre="Viral load reduction assay showing the dose-dependent anti-MERS-CoV activity of" exact="bexarotene" post="(10Î¼M). VeroE6 cells were infected with MERS-CoV (MOI ="/>
  <result pre="antivirals to reduce viral shedding in the gastrointestinal tract. Both" exact="abiraterone" post="acetate and bexarotene are non-chemotherapeutic antineoplastic drugs with limited"/>
  <result pre="viral shedding in the gastrointestinal tract. Both abiraterone acetate and" exact="bexarotene" post="are non-chemotherapeutic antineoplastic drugs with limited immunosuppressive effects. Abiraterone"/>
  <result pre="deprivation by inhibition of the androgen synthesizing enzyme CYP17A1 [33,34]." exact="Bexarotene" post="is a third-generation retinoid used in the treatment of"/>
  <result pre="and breast cancer [[35], [36], [37], [38]]. We showed that" exact="abiraterone" post="acetate and bexarotene potently inhibited SARS-CoV-2 replication in vitro"/>
  <result pre="[[35], [36], [37], [38]]. We showed that abiraterone acetate and" exact="bexarotene" post="potently inhibited SARS-CoV-2 replication in vitro with EC50 of"/>
  <result pre="1.94 Î¼M and 2.01 Î¼M, respectively. Of particular interest is" exact="bexarotene" post="which has a peak serum concentration (Cmax) of 3.39"/>
  <result pre="of 300 mg/m2 [39]. The Cmax to EC50 ratio of" exact="bexarotene" post="for SARS-CoV-2 (1.69) is higher than those achieved with"/>
  <result pre="than those achieved with standard dosing of chloroquine, hydroxychloroquine, and" exact="ivermectin" post="(0.02â€&quot;1.04). Moreover, the time required to achieve Cmax (Tmax)"/>
  <result pre="required to achieve Cmax (Tmax) with standard oral dosing of" exact="bexarotene" post="is short (2.5 h), which is important especially in"/>
  <result pre="adenovirus [21]. We therefore additionally tested the antiviral activity of" exact="bexarotene" post="against the highly virulent MERS-CoV, and showed that it"/>
  <result pre="MERS-CoV with an EC50 of 2.12 Î¼M. The potential of" exact="bexarotene" post="and its related analogue compounds as â€œpan-coronavirusâ€� agents should"/>
  <result pre="for COVID-19. The topical and/or systemic effects of cetilistat, diiodohydroxylquinoline," exact="abiraterone" post="acetate, and bexarotene should be further evaluated in suitable"/>
  <result pre="topical and/or systemic effects of cetilistat, diiodohydroxylquinoline, abiraterone acetate, and" exact="bexarotene" post="should be further evaluated in suitable ex vivo human"/>
  <result pre="drug discovery and therapeutic optionsNat. Rev. Drug Discov.15201632734726868298 12WangM.CaoR.ZhangL.YangX.LiuJ.XuM.ShiZ.HuZ.ZhongW.XiaoG.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
  <result pre="recently emerged novel coronavirus (2019-nCoV) in vitroCell Res.30202026927132020029 13GautretP.LagierJ.C.ParolaP.HoangV.T.MeddebL.MailheM.DoudierB.CourjonJ.GiordanengoV.VieiraV.E.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
  <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
  <result pre="Biochem. Mol. Biol.84200353754212767278 34ArasaratnamM.CrumbakerM.BhatnagarA.McKayMjMolloyMpGurneyH.Inter- and intra-patient variability in pharmacokinetics of" exact="abiraterone" post="acetate in metastatic prostate cancerCancer Chemother. Pharmacol.84201913914631081533 35BoehmM.F.ZhangL.ZhiL.McClurgM.R.BergerE.WagonerM.MaisD.E.SutoC.M.Design and"/>
  <result pre="apoptosis in leukemia cellsJ. Med. Chem.381995314631557636877 36GniadeckiR.AssafC.BagotM.DummerR.DuvicM.KnoblerR.RankiA.SchwandtP.WhittakerS.The optimal use of" exact="bexarotene" post="in cutaneous T-cell lymphomaBr. J. Dermatol.157200743344017553039 37DragnevK.H.PettyW.J.ShahS.J.LewisL.D.BlackC.C.MemoliV.NugentW.C.HermannT.Negro-VilarA.RigasJ.R.A proof-of-principle clinical"/>
  <result pre="cutaneous T-cell lymphomaBr. J. Dermatol.157200743344017553039 37DragnevK.H.PettyW.J.ShahS.J.LewisL.D.BlackC.C.MemoliV.NugentW.C.HermannT.Negro-VilarA.RigasJ.R.A proof-of-principle clinical trial of" exact="bexarotene" post="in patients with non-small cell lung cancerClin. Cancer Res.1320071794180017363535"/>
  <result pre="lung cancerClin. Cancer Res.1320071794180017363535 38EstevaF.J.GlaspyJ.BaidasS.LaufmanL.HutchinsL.DicklerM.TripathyD.CohenR.Multicenter phase II study of oral" exact="bexarotene" post="for patients with metastatic breast cancerJ. Clin. Oncol.212003999100612637463 39ListonD.R.DavisM.Clinically"/>
 </snippets>
</snippetsTree>
